RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
Regulatory Focus™ > News Articles > Case Study: A Novel Investment Partnering Solution for Sharing Development Risk

Case Study: A Novel Investment Partnering Solution for Sharing Development Risk

Posted 01 December 2008

On 24 July 2008, on its earnings call, Eli Lilly and Company announced its intention to partner with TPG-Axon and NovaQuest for the development of Lilly's two lead molecules for the treatment of Alzheimer's disease.1 One molecule is a gamma-secretase small molecule and the other is an antibody targeted against A-beta. Both molecules are designed to modify the progression of mild to moderate Alzheimer's disease.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe